Basel, Switzerland

Roche

Swiss healthcare company whose obesity candidates include assets from its acquisition of Carmot Therapeutics (agreement announced in December 2023) and from a 2025 collaboration with Zealand Pharma. These candidates, including enicepatide (CT-388) and petrelintide, are investigational and not approved. None of the molecules currently in this atlas are listed as Roche products.

Carmot Therapeutics acquisition

On 4 December 2023 Roche announced a merger agreement to acquire Carmot Therapeutics for $2.7 billion upfront plus up to $400 million in milestone payments. The deal included CT-388, a once-weekly GLP-1/GIP dual agonist, and two other obesity or diabetes candidates.[src]

Zealand Pharma petrelintide collaboration

On 12 March 2025 Roche announced an exclusive collaboration and licence agreement with Zealand Pharma to co-develop and co-commercialise petrelintide, a long-acting amylin analogue. Roche stated upfront payments totalling $1.65 billion ($1.4 billion due at closing and $250 million over the first two anniversaries) and total potential consideration of up to $5.3 billion including milestones.[src]

Enicepatide (CT-388) Phase 3 registration

ClinicalTrials.gov lists Hoffmann-La Roche as sponsor of a Phase 3 trial of enicepatide (CT-388, RO7795068) in adults (18 and over) with obesity or overweight without type 2 diabetes (Enith1), with an actual start date of 16 March 2026 and a planned 2,000 participants.[src]